TEST CHANGE

Virilization Panel 1

2002028, VIRIL PANEL

Specimen Requirements:	
Patient Preparation:	
Collect:	Serum separator tube or green (sodium or lithium heparin). Collect between 6-10 a.m. Also acceptable: Lavender (EDTA).
Specimen Preparation:	Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min 0.5 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	
Remarks:	
Stability:	Ambient: 2 hours; Refrigerated: 1 week; Frozen: 6 months
Methodology:	Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed:	Sun-Sat
Reported:	1-54 days
Note:	
CPT Codes:	82157; 82626; 84403
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

Free or bioavailable testosterone measurements may provide supportive information.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Test Number	Components	Reference Interval		
	Testosterone by Mass Spec			
		Age	Male (ng/dL)	Female (ng/dL)
		Premature (26-28 weeks)	59-125	5-16
		Premature (31-35 weeks)	37-198	5-22
		Newborn	75-400	20-64
		1-5 months	14-363	Less than 20
		6-24 months	Less than 37	Less than 9
		2-3 years	Less than 15	Less than 20
		4-5 years	Less than 19	Less than 30
		6-7 years	Less than 13	Less than 7
		8-9 years	2-8	1-11
		10-11 years	2-165	3-32
		12-13 years	3-619	6-50
		14-15 years	31-733	6-52
		16-17 years	158-826	9-58
		18-39 years	300-1080	9-55
		40-59 years	300-890	9-55
		60 years and older	300-720	5-32
		Premenopausal (18 years and older)	Not Applicable	9-55
		Postmenopausal	Not Applicable	5-32
		Tanner Stage I	2-15	2-17
		Tanner Stage II	3-303	5-40
		Tanner Stage III	10-851	10-63
		Tanner Stage IV-V	162-847	11-62
	Androstenedione by TMS			

		Age	Male (ng/mL)	Female (ng/mL)
		Premature Infants (26-28 weeks Day 4)	0.92-2.82	0.92-2.82
		Premature Infants (31-35 weeks Day 4)	0.80-4.46	0.80-4.46
		Full Term Infants (1-7 days)	0.20-2.90	0.20-2.90
		8-30 days	0.18-0.80	0.18-0.80
		1-5 months	0.06-0.68	0.06-0.68
		6-24 months	0.03-0.15	Less than 0.15
		2-3 years	Less than 0.11	Less than 0.16
		4-5 years	0.02-0.17	0.02-0.21
		6-7 years	0.01-0.29	0.02-0.28
		8-9 years	0.03-0.30	0.04-0.42
		10-11 years	0.07-0.39	0.09-1.23
		12-13 years	0.10-0.64	0.24-1.73
		14-15 years	0.18-0.94	0.39-2.00
		16-17 years	0.30-1.13	0.35-2.12
		18-39 years	0.33-1.34	0.26-2.14
		40 years and older	0.23-0.89	0.13-0.82
		Premenopausal	Not Applicable	0.26-2.14
		Postmenopausal	Not Applicable	0.13-0.82
		Tanner Stage I	0.04-0.32	0.05-0.51
		Tanner Stage II	0.08-0.48	0.15-1.37
		Tanner Stage III	0.14-0.87	0.37-2.24
		Tanner Stage IV-V	0.27-1.07	0.35-2.05
	Dehydroepiandrosterone by TMS			

Age	Male (ng/mL)	Female (ng/mL)
Premature	Less than 40	Less than 40
0-1 days	Less than 11	Less than 11
2-6 days	Less than 8.7	Less than 8.7
7 days-1 month	Less than 5.8	Less than 5.8
1-5 months	Less than 2.9	Less than 2.9
6-24 months	Less than 2.5	Less than 1.99
2-3 years	Less than 0.63	Less than 0.85
4-5 years	Less than 0.95	Less than 1.03
6-7 years	0.06-1.93	Less than 1.79
8-9 years	0.10-2.08	0.14-2.35
10-11 years	0.32-3.08	0.43-3.78
12-13 years	0.57-4.10	0.89-6.21
14-15 years	0.93-6.04	1.22-7.01
16-17 years	1.17-6.52	1.42-9.00
18-39 years	1.33-7.78	1.33-7.78
40 years and older	0.63-4.70	0.63-4.70
Postmenopausal	Not Applicable	0.60-5.73
Tanner Stage I	0.11-2.37	0.14-2.76
Tanner Stage II	0.37-3.66	0.83-4.87
Tanner Stage III	0.75-5.24	1.08-7.56
Tanner Stage IV-V	1.22-6.73	1.24-7.88